Hemostatic Agents Market - Snapshot

The global hemostatic agents market is expanding due to increasing number of surgical procedures across the globe. The global hemostatic agents market was valued at more than US$ 2.8 Bn in 2015. It is expected to expand at a compound annual growth rate (CAGR) of over 6.0% from 2018 to 2022 to reach the value of US$ 4.1 Bn by 2022. The global market is expanding at a relatively higher growth rate owing to an increase in the geriatric population, adoption of hemostatic products to curb bleeding, and rise in research and development in both developed and developing markets.

Hemostasis is a process that involves stoppage of bleeding or blood flow through a blood vessel, or hemorrhage. In hemostasis, a clot is formed at the injured area, thereby repairing the blood vessel. Hemostasis consists of primary hemostasis, secondary hemostasis, and fibrinolysis. In case of a blood vessel injury, platelets combine together to form a plug. An interaction of proteins occurs, known as clotting factors, for the formation of a fibrin mesh to hold the platelets in place. This results in the healing of the injury, while preventing blood from escaping the blood vessel. Hemostatic agents are utilized to stem blood flow via the increased promotion of clotting, thereby improving the hemostasis by accelerating the coagulation process. These agents enhance hemostasis by progressing primary hemostasis, increasing fibrin formation, or inhibiting fibrinolysis. Hemostatic agents play a vital role in the treatment or prevention of bleeding, thereby indicating their usage in various therapeutic areas. According to a study by U.S. Army Institute of Surgical Research (USAISR), the survivability rate drops to just 14% if blood loss continues and the patient goes into Stage II shock or greater.

hemostatic agents market

The global hemostatic agents market has been broadly segmented based on product type, specialty / therapeutic area, size of hospitals, and region. In terms of product type, the market has been classified into active, passive, and combination products. Active agents are expected to hold a significant share of the market and are differentiated from passive hemostats by their thrombin content and due to their improved efficacy, thrombin-based hemostats, i.e. active agents, is projected to expand at a significant CAGR during the forecast period. Passive agents, also called mechanical agents, are not often used in procedures, such as spinal surgeries, in which active agents and combinations are preferred. In certain cases, passive hemostat’s “stickiness” to both instruments and tissues is an additional hindrance to its use. Therefore, the passive segment of the market is estimated to expand at a CAGR 3.43% during the forecast period. However, since they are the oldest hemostatic agents they, currently, hold a considerable market share.
In terms of specialty / therapeutic area, the global hemostatic agents market has been segregated into cardiology, cath lab, trauma, general surgery, OB/GYN, transplant, oncology, neurology, orthopedic, plastic surgery, dental, and others (urological surgeries, pulmonary surgeries). General surgery, cardiology, and trauma segments are expected to hold a major share of the market during the forecast period due to the increase in number of cases in these therapeutic areas. In 2015, according to CDC, in the U.S., approximately 610,000 people die due to heart disease, every year, accounting 1 in every 4 deaths, and coronary heart disease (CHD) is considered to be the most common type of heart disease, causing the death of 370,000 people per year.

In terms of size of hospitals, the global hemostatic agents market has been divided into large hospitals (500+ bed size), medium hospital (250-499 beds), and small hospitals (less than 250 beds). Large hospitals and medium hospitals segments are expected to maintain their dominance and gain market share by the end of the forecast period. Availability of well-equipped infrastructure, facilities, resources, high surgery volume, and medical professionals & care has led to their prominent share in the global market. Partnerships and network by prominent hospitals with key players in the hemostatic agents market, is also the reason for their increased market share.

In terms of region, the global hemostatic agents market has been segmented into North America, Europe, Asia Pacific, South Africa, and RoW. North America dominated the global market and is expected to maintain its dominance by the end of 2022. The market in North America is predominantly driven by rapid increase in geriatric population, rise in number of surgical procedures, and increase in patient population. Moreover, increasing number of players and products, coupled with sturdy focus on research and development, is a key factor driving the market in the U.S. The market in Asia Pacific is projected to expand at a prominent CAGR during the forecast period. Increasing population, initiatives taken by governments in healthcare, and rise in research and development activities are key factors driving the market in Asia Pacific.
Companies such as Baxter, Ethicon US, LLC., Pfizer Inc., and C. R. Bard, Inc. accounted for a major share of the global market in 2015. Strong network with hospitals and distributors, effective and wide product lines, and extensive involvement in research and development, are key factors boosting the position of these players in the market. In January 2018, Ethicon US, LLC., launched a powdered adjunctive hemostat, called Surgicel powder absorbable hemostat. It is utilized to help surgeons efficiently and effectively control disruptive bleeding. In March 2018, Baxter completed the acquisition of RECOTHROM and PREVELEAK, thus broadening its surgical hemostat and sealant portfolio. Companies are focused on strategic collaborations and acquisitions with parallel companies to strengthen their presence in the global market.

Hemostatic Agents Market - Overview

Hemostasis is the physiological process to stop the bleeding, or blood flow via a blood vessel, or hemorrhage. A clot is formed at injury site in hemostasis and results in repairing of blood vessels. The main components of hemostasis are primary hemostasis, secondary hemostasis, and fibrinolysis. At the time of a blood vessel injury, platelets gather together to form a plug. In hemostasis, an interaction of proteins, known as clotting factors, forms a fibrin mesh to hold the platelets intact, thereby resulting in the injury healing while not letting the blood escape from the blood vessel. Hemostatic agents are utilized to stem blood flow and enhance clotting and hemostasis by speeding up the coagulation process. These agents enhance hemostasis by progressing primary hemostasis, boosting the formation of fibrin, or inhibiting fibrinolysis. Hemostatic agents play a prominent and vital role in the treatment or prevention of excessive or disruptive blood flow, thereby indicating their importance and use in treatments in various therapeutic areas. According to JEMS (Journal of Emergency Medical Services), traumatic and non-traumatic causes of hemorrhage carry remarkable morbidity and mortality.

Rise in the geriatric population, increase in number of surgical procedures, research & developments, and advancements in the fields of healthcare and life sciences, rise in public health awareness and measures  have led to the introduction of appropriate and effective treatments for diseases. Consistent rise in geriatric population requiring treatments in various therapeutic areas fuels the demand for hemostatic agents in order to prevent the disruptive blood loss. This provides significant opportunity for key players operating in the market. Key players are introducing different strategies of launching products and acquisitions, along with appropriate marketing and strong distributors and hospitals network, thereby boosting the hemostatic agents market.

Acquisition and collaboration of related companies, along with the launch of new products after extensive research and development activities, has been a key strategy adopted by key players to strengthen their geographic presence in the last few years. Therefore, the players strive to gain competitive advantage in the market by opting for strategies such as agreements, partnerships and collaborations, and new product development.

The global hemostatic agents market has been broadly segmented based on product type, specialty / therapeutic area, size of hospitals, and region. In terms of product type, the global hemostatic market has been divided into active agents, passive agents, and combination. The active agents segment, followed by the combination segment, is expected to expand during the forecast period. In terms of specialty / therapeutic area, the global hemostatic agents market has been classified into cardiology, cath lab, trauma, general surgery, obgyn, transplant, oncology, neurology, orthopedic, plastic surgery, dental, and others (urological surgeries, pulmonary surgeries). General surgery, cardiology, and trauma, segments are expected to dominate the market during the forecast period due to the increase in number of patient population cases in these therapeutic areas. In terms of size of hospitals, the global hemostatic agents market has been divided into large hospitals (500+ bed size), medium hospital (250-499 beds), and small hospitals (less than 250 beds). Large hospitals and medium hospitals segments are expected to hold a major share of the market during the forecast period.

In terms of region, the global hemostatic agents market has been segmented into North America, Europe, Asia Pacific, South Africa and Rest of World (RoW). North America and Europe holds a prominent share of the global hemostatic agents market. The market in North America is primarily driven by the increase in geriatric population, rise in number of surgical procedures, and increase in patient population. The market in Asia Pacific is expected to expand at a significant growth rate during the forecast period. The report also states key players in the market based on various attributes such as company overview, key business strategies, financial overview, recent developments, and product portfolio. Key players functioning in the global hemostatic agents market include Baxter, Ethicon US, LLC., C. R. Bard, Inc., B. Braun Melsungen AG, Pfizer Inc., Z-Medica, LLC., CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, and GELITA AG.

The global hemostatic agents market has been segmented as mentioned below:

Global Hemostatic Agents Market, by Product Type

  • Active Agents
  • Passive Agents
  • Combination

Global Hemostatic Agents Market, by Specialty / Therapeutic Area

  • Cardiology
  • Cath Lab
  • Trauma
  • General Surgery
  • ObGyn
  • Transplant
  • Oncology
  • Neurology
  • Orthopedic
  • Plastic Surgery
  • Dental
  • Others (Urological Surgeries, Pulmonary Surgeries)

Global Hemostatic Agents Market, by Size of Hospitals

  • Large Hospitals (500+ bed size)
  • Medium Hospital (250-499 beds)
  • Small Hospitals (less than 250 beds)

Global Hemostatic Agents Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Australia
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • South Africa
  • Rest of World (RoW)
.